SCHEMBL4675337

SCHEMBL4675337

O=C(C=C(O)c1nc[nH]n1)c1cc(C(=O)c2ccccc2)n(S(=O)(=O)c2ccc(F)cc2)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 3/20 0.35
ALDH3A1 P30838 1/20 0.34
POLB P06746 1/20 0.34
KMT2A Q03164 1/20 0.32
ITGB1 P05556 1/20 0.31
ITGA2 P17301 1/20 0.31
NOD2 Q9HC29 1/20 0.31
NOD1 Q9Y239 1/20 0.31
GRM4 Q14833 1/20 0.31
PPME1 Q9Y570 1/20 0.31
PKM P14618 2/20 0.31
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 1/20 0.30
HPGD P15428 1/20 0.30
HDAC3 O15379 1/20 0.30
HDAC4 P56524 1/20 0.30
HDAC1 Q13547 1/20 0.30
HDAC7 Q8WUI4 1/20 0.30
HDAC2 Q92769 1/20 0.30
HDAC10 Q969S8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4676191 0.93 PTGS2 (0.35) PTGS2ALDH3A1POLBKMT2AITGB1
SCHEMBL4671838 0.91 CA2 (0.35) PTGS2ALDH3A1POLBNOD2NOD1
SCHEMBL4671158 0.91 KMT2A (0.32) ALDH3A1POLBKMT2AHDAC3HDAC4
SCHEMBL4673557 0.87 KMT2A (0.32) ALDH3A1POLBKMT2AHDAC3HDAC4
SCHEMBL4672034 0.85 PTGDR2 (0.34) PTGS2ALDH3A1POLBKMT2AITGB1
SCHEMBL4676188 0.85 NOD2 (0.42) PTGS2NOD2NOD1ALDH1A1
SCHEMBL5899366 0.84 CA2 (0.35) PTGS2ALDH3A1NOD2NOD1GRM4
SCHEMBL4671826 0.81 CHRNA7 (0.41) PTGS2NOD2NOD1ALDH1A1
SCHEMBL4678210 0.81 CA2 (0.34) ALDH3A1PKMALDH1A1
SCHEMBL4673689 0.81 SGMS1 (0.35) PTGS2ALDH3A1KMT2ANOD2NOD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 PTGS2 4586/4885ALDH3A1 394/4885POLB 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.